SCHEMBL26611501

SCHEMBL26611501

[N-]=[N+]=NCCOCCn1ccc([N+](=O)[O-])n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.41
LMNA P02545 2/20 0.41
POLB P06746 2/20 0.40
PKM P14618 2/20 0.40
MGMT P16455 1/20 0.39
KMT2A Q03164 3/20 0.38
GAA P10253 3/20 0.36
CYP1A2 P05177 2/20 0.35
CYP3A4 P08684 2/20 0.35
CYP2C19 P33261 2/20 0.35
RECQL P46063 1/20 0.35
CYP2D6 P10635 1/20 0.35
MEN1 O00255 1/20 0.35
F2 P00734 2/20 0.34
PLAU P00749 2/20 0.34
KLKB1 P03952 2/20 0.34
ELANE P08246 2/20 0.34
MMP2 P08253 1/20 0.33
MMP9 P14780 1/20 0.33
MMP8 P22894 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1862200 0.76 ALDH1A1 (0.46) ALDH1A1LMNAPOLBPKMKMT2A
SCHEMBL21962049 0.75 HDAC3 (0.48) ALDH1A1LMNAPOLBPKMKMT2A
SCHEMBL26611984 0.73 MGMT (0.43) MGMT
SCHEMBL1861657 0.72 ALDH1A1 (0.46) ALDH1A1LMNAPOLBPKMKMT2A
SCHEMBL28782143 0.72 CA12 (0.44) LMNAMGMTKMT2ACYP2C19
SCHEMBL18235433 0.71 ALDH1A1 (0.43) ALDH1A1LMNAPOLBPKMKMT2A
SCHEMBL27859546 0.71 PKM (0.42) ALDH1A1LMNAPOLBPKMKMT2A
SCHEMBL27859547 0.71 PKM (0.42) ALDH1A1LMNAPOLBPKMKMT2A
SCHEMBL21961350 0.71 ALDH1A1 (0.44) ALDH1A1LMNAPOLBPKMKMT2A
SCHEMBL13011203 0.70 POLB (0.49) ALDH1A1LMNAPOLBPKMKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4511379-A2 THERANOSTIC SILICON-FLUORIDE HETEROAROMATIC SYSTEMS AND METHODS THEREOF Fuzionaire Theranostics, Inc. (US) 2025-02-26 EP disclosed
CN-119301134-A Silicon fluoride heteroaromatic systems for theranostics and methods therefor 富齐奥奈尔治疗诊断股份有限公司 2025-01-10 CN disclosed
US-20230355813-A1 Theranostic Silicon-Fluoride Heteroaromatic Systems and Methods Thereof FUZIONAIRE DIAGNOSTICS, INC. (US) 2023-11-09 US disclosed
US-20230355813-A1 Theranostic Silicon-Fluoride Heteroaromatic Systems and Methods Thereof FUZIONAIRE DIAGNOSTICS, INC. (US) 2023-11-09 US disclosed
WO-2023205755-A2 THERANOSTIC SILICON-FLUORIDE HETEROAROMATIC SYSTEMS AND METHODS THEREOF FUZIONAIRE DIAGNOSTICS, INC. (US) 2023-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230355813-A1 Theranostic Silicon-Fluoride Heteroaromatic Systems and Methods Thereof FRS2, PAICS, FGF23 ALDH1A1 3761/4885LMNA 3403/4885POLB 3568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.